ARID1A and breast cancer: Based on the results, the researchers claimed that the increased expression of ARID1A was a biomarker for poor prognosis in HER2+ BC, a claim supported by some [141] but contested by others [142,143], although it should be noted that the definition of “resistance to trastuzumab” varied slightly between different studies.